Robert F. Kennedy Jr. has increased the number of supporters on an FDA advisory panel to advocate for the approval of injectable peptide drugs, which the FDA has deemed ineffective and potentially unsafe. The upcoming panel meetings will evaluate multiple peptide drugs for various uses, raising concerns about regulatory integrity and safety assessment.
Robert F. Kennedy Jr., a critic of vaccine policies, has reshaped an FDA advisory panel by adding nine members who advocate for peptide use, raising the total number of advisors to 13. This change coincides with Kennedy's agenda to challenge the FDA's current stance against these injectable peptide drugs.
The newly appointed members primarily have financial connections to wellness clinics promoting peptide therapies, which raises questions about conflicts of interest within the panel.
Earlier in 2023, FDA scientists concluded that the peptide drugs lack adequate evidence proving their benefits and may present safety hazards. Despite these findings, Kennedy is pushing for a reevaluation of the FDA's restrictive policies on these drugs.
The advisory panel's meetings are scheduled for July 23 and 24, where the focus will be on several peptides, including BPC-157 and emideltide, among others. A portion of these meetings will determine if these peptides should be available for compounding pharmacies to produce, which currently they are not allowed to do for human use.
The discussions will revolve around the safety and efficacy of each peptide, despite the FDA's consistent warning against their use based on research capacity.
Kennedy's efforts to stack the panel with pro-peptide advocates increase the likelihood of the advisory committee siding with the interests of peptide promoters. This shift poses significant implications for future regulatory practices and public health, particularly regarding the approval of unproven therapies.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
Robert F. Kennedy Jr. has increased the number of supporters on an FDA advisory panel to advocate for the approval of injectable peptide drugs, which the FDA has deemed ineffective and potentially unsafe. The upcoming panel meetings will evaluate multiple peptide drugs for various uses, raising concerns about regulatory integrity and safety assessment.